Evidence map›Paper›PMID 23487450›Full record

ArticleJournal of virology2013

tat Exon 1 exhibits functional diversity during HIV-1 subtype C primary infection.

Raabya Rossenkhan, Iain J MacLeod, Theresa K Sebunya, Eduardo Castro-Nallar, Mary Fran McLane, Rosemary Musonda, Berhanu A Gashe, Vlad Novitsky, M Essex

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Genome-wide association study reveals genetic variants associated with HIV-1C infection in a Botswana study population.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  7. Addressing an HIV cure in LMIC.Retrovirology · 2021
    Review
  8. Article
  9. Genetic variation and function of the HIV-1 Tat protein.Medical microbiology and immunology · 2019
    Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Raabya RossenkhanDepartment of Biological Sciences, University of Botswana, Gaborone, Botswana.
Iain J MacLeod
Theresa K Sebunya
Eduardo Castro-Nallar
Mary Fran McLane
Rosemary Musonda
Berhanu A Gashe
Vlad Novitsky
M Essex
Harvard University · USUniversity of Botswana · BWBotswana Harvard AIDS Institute Partnership · BWGeorge Washington University Virginia Campus · US

Funding

INTERNATIONAL TRAINING IN AIDS-RELATED EPIDEMIOLOGYD43TW000004 · FIC · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ESSEX, MYRON E · 1988 to 2012
$13.4M
Markers of Viral Set Point in Primary HIV-1C InfectionR01AI057027 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI NOVITSKY, VLADIMIR A · 2005 to 2009
$2.2M
FIC NIH HHS D43 TW000004NIAID NIH HHS R01 AI057027
6 · The paper itself

Abstract

Human immunodeficiency virus type 1 (HIV-1) Tat is a mediator of viral transcription and is involved in the control of virus replication. However, associations between HIV-1 Tat diversity and functional effects during primary HIV-1 infection are still unclear. We estimated selection pressures in tat exon 1 using the mixed-effects model of evolution with 672 viral sequences generated from 20 patients infected with HIV-1 subtype C (HIV-1C) over 500 days postseroconversion. tat exon 1 residues 3, 4, 21, 24, 29, 39, and 68 were under positive selection, and we established that specific amino acid signature patterns were apparent in primary HIV-1C infection compared with chronic infection. We assessed the impact of these mutations on long terminal repeat (LTR) activity and found that Tat activity was negatively affected by the Ala(21) substitution identified in 13/20 (65%) of patients, which reduced LTR activity by 88% (± 1%) (P < 0.001). The greatest increase in Tat activity was seen with the Gln(35)/Lys(39) double mutant that resulted in an additional 49% (± 14%) production of LTR-driven luciferase (P = 0.012). There was a moderate positive correlation between Tat-mediated LTR activity and HIV-1 RNA in plasma (P = 0.026; r = 0.400) after 180 days postseroconversion that was reduced by 500 days postseroconversion (P = 0.043; r = 0.266). Although Tat activation of the LTR is not a strong predictor of these clinical variables, there are significant linear relationships between Tat transactivation and patients' plasma viral loads and CD4 counts, highlighting the complex interplay between Tat mutations in early HIV-1C infection.

Indexed as

Virus ReplicationAdultAmino Acid SubstitutionCD4 Lymphocyte CountEvolution, MolecularFemaleGenetic VariationHIV-1HIV InfectionsHIV Long Terminal RepeatHumansMaleMutation, MissensePlasmaSelection, Genetictat Gene Products, Human Immunodeficiency Virustat Gene Products, Human Immunodeficiency Virus

Identifiers

PMID23487450
PMCPMC3648179
OpenAlexW2008340941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.